Heron Therapeutics (HRTX) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Verrica Pharmaceuticals (VRCA) has outperformed Heron Therapeutics (HRTX) over the past year, losing 34.9% versus a loss of 76.2%. Over five years, HRTX leads with a -97.3% price change compared with -97.4% for VRCA. Heron Therapeutics is the larger company by market cap ($48.0 million vs $47.1 million), about 1.0 times the size, while Verrica Pharmaceuticals is growing revenue faster (+370.2% vs +7.4%).
Heron Therapeutics converts more of its revenue into profit, with a net margin of -13.0% versus -50.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | VRCA |
|---|---|---|
| Share price | $0.2525 | $2.74 |
| Market cap | $48.04M | $47.07M |
| 1-day change | -4.39% | -5.03% |
| YTD return | -80.58% | -67.03% |
| 1-year return | -76.18% | -34.92% |
| 5-year return | -97.32% | -97.38% |
| EPS (TTM) | $-0.11 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $154.90M | $35.58M |
| Revenue growth (YoY) | +7.36% | +370.22% |
| Net income (latest FY) | $-20.20M | $-17.89M |
| Gross margin | 73.31% | — |
| Operating margin | -1.64% | -34.25% |
| Net margin | -13.04% | -50.27% |
| 52-week high | $1.58 | $9.82 |
| 52-week low | $0.2479 | $2.73 |
| Distance from 52-week high | -84.02% | -72.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2672.28% | +404.74% |
| Average volume | 4.56M | 68.78K |
| Shares outstanding | 190.27M | 17.18M |
| Employees | 128 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRCA has outperformed HRTX by 41.3 percentage points over the past year.
- Heron Therapeutics is more profitable, keeping -13.0 cents of every revenue dollar as net income versus -50.3 cents for Verrica Pharmaceuticals.
- Verrica Pharmaceuticals grew revenue faster in its latest fiscal year (+370.22% vs +7.36%).
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
HRTX vs VRCA FAQ
Which is bigger, Heron Therapeutics or Verrica Pharmaceuticals?
Heron Therapeutics (HRTX) is larger, with a market capitalization of $48.04M compared with $47.07M for Verrica Pharmaceuticals (VRCA).
Which stock has performed better over the past year, HRTX or VRCA?
VRCA returned -34.92% over the past 12 months, compared with -76.18% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.